Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01892345 : A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study)
PhasePhase 3
AgesMin: 18 Years Max: N/A
Eligibility
Key Inclusion Criteria:

1. Male or female patients ? 18 years old

2. Diagnosis of NMO or NMO spectrum disorder

3. All patients must be NMO-IgG seropositive

4. Clinical evidence of at least 2 relapses in last 12 months or 3 relapses in the last
24 months (with at least 1 relapse in the 12 months prior to the Screening)

5. EDSS score ?7

6. Immunosuppressive therapy is allowed provided patients have been on a stable
maintenance dose prior to the Screening and remain on a stable dose for the duration
of the study

Key Exclusion Criteria:

1. Use of rituximab within 3 months prior to screening

2. Use of mitoxantrone within 3 months prior to screening

3. Use of IVIg within 3 weeks prior to screening
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01892345      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740